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Ricin is a potent toxin and a potential bioterrorism weapon with no specific countermeas-
ures or vaccines available. The holotoxin is composed of two polypeptide chains linked by a
single disulfide bond: the A-chain (RTA), which is an N-glycosidase enzyme, and the B-chain
(RTB), a lectin polypeptide that binds galactosyl moieties on the surface of the mammalian
target cells. Previously (McHugh et al.), a recombinant truncated form of RTA (rRTA1-33/
44-198 protein, herein denoted RVEaTM) expressed in Escherichia coli using a codon-opti-
mized gene was shown to be non-toxic, stable, and protective against a ricin challenge in
mice. Here, we describe the process development and scale-up at the 12 L fermentation
scale, and the current Good Manufacturing Practice (cGMP)-compliant production of
RVEcTM at the 40 L scale. The average yield of the final purified bulk RVEcTM is approxi-
mately 16 g/kg of wet cell weight or 1.2 g/L of fermentation broth. The RVEcTM was [99%
pure by three HPLC methods and SDS-PAGE. The intact mass and peptide mapping analysis
of RVEcTM confirmed the identity of the product and is consistent with the absence of
posttranslational modifications. Potency assays demonstrated that RVEcTM was immuno-
protective against lethal ricin challenge and elicited neutralizing anti-ricin antibodies in
95–100% of the vaccinated mice. Published 2011 American Institute of Chemical Engineers
Biotechnol. Prog., 27: 1036–1047, 2011
Keywords: novel vaccine candidate, process development, cGMP lot of vaccine
Introduction
The ricin toxin is a 64 kilodalton (kDa) protein produced
by the seeds of the castor oil plant (Ricinus communis). The
mechanism of action of this opportunistic ribotoxin has been
thoroughly studied.1,2 The holotoxin is a glycosylated hetero-
dimeric protein that is composed of two chains, A and B,
joined by a single disulfide bond.3–5 The A-chain (RTA) is
an enzyme that inactivates the 28S ribosomal ribonucleic
acid (rRNA) by hydrolytic cleavage of the N-glycosidic
bond of the essential adenine nucleotide (A4324) of the ribo-
some.6,7 The depurination site in the rRNA is part of a con-
served sequence present in nearly all eukaryotic cells and it
is known as the sarcin-ricin loop.8 The B-chain (RTB) is a
lectin that binds to galactose moieties presented by cell-sur-
face glycopeptides or glycolipids, inducing endocytosis of
the holotoxin. The combination of the internalization by the
toxin and the cytosolic activity of the A-chain (kcat/Km
107 M1 s1)6 allows a single ricin molecule to kill a eu-
karyotic cell by damaging protein synthesis.9 The holotoxin
is taken up by cells through endocytosis, incorporated into
vesicles, and transported through the Golgi complex until it
reaches the endoplasmic reticulum.1 Therein the disulfide
bond is reduced, causing the RTA chain to undergo partial
unfolding, and allows it to cross the endoplasmic reticulum
into the cytosol. The active depurinase form of RTA is then
reconstituted. Outside the cytosol, RTA tends to undergo
aggregation, a factor which has significantly slowed down
efforts toward development of a vaccine.10
Interest in the development of a vaccine against ricin has
increased in recent years due to threats of bioterrorism and
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the wide availability of castor beans. The Centers for Dis-
ease Control and Prevention (CDC) has classified ricin as a
level B biothreat agent. One well-known case was the death
of a Bulgarian dissident reported in the 1970s, caused by a
single ricin pellet.11 On the basis of animal studies, the lethal
ricin dose in humans is believed to be 1–25 lg/kg11–13
although such toxicity level occurs only when the toxin is
administered either by inhalation or injection.
Previously, protective immunity against ricin was demon-
strated in animal models by vaccinating with formalin-
treated ricin toxoid14 and by passive immunity using anti-
ricin IgG.15,16 Because of the potential for reversion of the
formalin-inactivated toxoid to its toxic form and the short-
comings of antibody therapy (cannot neutralize toxin once it
has entered cells), other approaches to vaccine development
have been investigated. One approach has been to identify
essential amino acid residues for enzymatic activity and utilize
mutants as potential vaccine candidates. Among those that
have been identified include tyrosine (Tyr) 80, Tyr 123, gluta-
mate (Glu) 177, arginine (Arg) 180, asparagine (Asn) 209, and
tryptophan (Trp) 211.17,18 Although several mutants of RTA
have been generated that confer immunoprotection against ricin
in animal models, they retain the biophysical tendency to ag-
gregate and precipitate in aqueous environments due to the
instability of RTA in the absence of RTB, rendering them inef-
fective for vaccine process development. A successful approach
to stabilizing an RTA derivative using protein engineering and
recombinant DNA technology has been reported.19,20
In this approach, a comparative computational analysis of
RTA and the similar ribosome-inactivating protein from
pokeweed, which is composed of a single monomeric chain,
was undertaken. Removal of the highly hydrophobic C-ter-
minus amino acid region (199–267) resulted in a protein
with a significant decrease in its behavior for aggregating
and precipitating in aqueous solutions. Because residues Asn
209, Trp 211, and Arg 213 are required for rRNA binding, the
truncated protein is devoid of N-glycosidase activity and it is
therefore not toxic. To further increase stability, a disordered
non-immunogenic exposed loop comprised of residues 34–43
was also deleted. This construct behaves as a monodisperse
monomer with a secondary protein structure almost identical to
that of native RTA; it effectively protected mice against an
aerosolized or injected ricin toxin challenge. Furthermore,
reformulation of this protein from phosphate-buffered saline
into succinate buffer increased the adherence of the protein to
aluminum hydroxide adjuvant up to 91%, resulting in a three-
fold increase in immunogenicity in a mouse model.21 The
recombinant form of RTA 1-33/44-198 expressed in Esche-
richia coli (herein called RVEcTM) constitutes a promising can-
didate for a vaccine against the ricin toxin. This manuscript
describes the process development of RVEcTM starting with
strain construction through cGMP production of clinical grade
vaccine for evaluation in a Phase I clinical study.
Materials and Methods
Analytical methods
Analytical methods were developed for in-process, release,
and characterization of RVEc. Table 1 provides a list of rou-
tine analytical methods that were developed and their critical
attributes. The text below describes methods that required
significant development, that is, peptide mapping, intact
mass analysis, potency assay, and an assay for residual test-
ing of kanamycin.
Peptide Mapping of RVEcTM. To perform the trypsin
digest, a solution of 20 lg of RVEcTM was adjusted to 50
mM ammonium carbonate by adding 500 mM ammonium
carbonate, pH 7.8 stock solution. Samples were reduced with
dithiothreitol (5 mM final concentration) for 60 min at 25C,
alkylated with iodoacetamide (10 mM final concentration) in
the dark for 30 min at ambient temperature, digested with
trypsin (1:20 E:S w/w ratio) for 18 h at 25C, and then
quenched with by adjusting to a final formic acid concentra-
tion of 0.1% (v/v).
The trypsin digest was analyzed with a Dionex Acclaim
PepMap C18 column (1 mm  150 mm, 3 lm particles, 100
Å pores). Solvent A was 0.1% (v/v) formic acid in water
and Solvent B was 0.1% formic acid in 50/50 acetonitrile/
water. The tryptic peptides were separated by a two step lin-
ear gradient (2–10% B in 10 min then 10–100% B in 90
min) at a flow rate of 53 lL/min and monitored at 214 nm.
The cyanogen bromide digest started with a solution con-
taining 50 lg of RVEcTM frozen at 80C for 2 h and then
evaporated to dryness in a centrifugal evaporator without
additional heating. The sample was reconstituted in 50 lL of
50 mM ammonium carbonate, pH 7.8. DTT was added to 5
mM, a layer of nitrogen gas was placed over the solution,
and the sample was incubated for 18 h at 25C. The sample
was then frozen as before and evaporated to dryness in a
centrifugal evaporator without additional heating. The sam-
ple was reconstituted in 70% formic acid to a protein con-
centration of 0.5 mg/mL. Cyanogen bromide was added
from a 5 M stock to a final concentration of 250 mM cyano-
gen bromide. The samples were incubated for 18–24 h in the
dark. After digestion, samples were quenched with 2.5 M
methionine and incubated for 18 h at 25C.
The cyanogen bromide digests were analyzed immediately
using RP-HPLC with a Grace Vydac C18 column, 4.6 mm 
100 mm, 3 lm particles, 300 Å pores. Samples were diluted
with an equal volume of Solvent A [5% acetonitrile, 0.1%
(v/v) TFA in water] and centrifuged at 14,000g for 10 min
before being placed in autosampler vials. Solvent B contained
0.1% TFA in 95% acetonitrile and 5% water. The digested
peptides were separated by a linear gradient (0–75% B in 10
min) at a flow rate of 2.5 mL/min and monitored at 214 nm.
LC-MS/MS using a nanoflow LC system (Dionex Ultimate
3000 with UV detector) and an Applied Biosystems 4000
QTrap mass spectrometer (ABI-Sciex) was used to identify
peptides in the tryptic map. Solvent A was 0.1% (v/v) formic
acid (Fluka) in water; Solvent B was 0.1% (v/v) formic acid
in acetonitrile (Burdick and Jackson). The column was a
Dionex Acclaim C18 PepMap (75 lm  15 cm), with a
flow rate of 300 nL/min, in a column oven set at 45C. A
gradient of 5–50% B over 90 min eluted the peptides. Infor-
mation-dependent-acquisition (IDA) methods were used to
collect MS and MS/MS data. All peptide identities were con-
firmed by manual inspection of MS/MS data.
ESI/TOF Intact Mass Analysis and N-Terminus
Methionine Determination. Mass spectra of intact proteins
were obtained using an Agilent 6210 TOF mass spectrometer
equipped with an Agilent 1200 HPLC and orthogonal elec-
trospray ionization (ESI) source. Protein samples were
loaded onto an Agilent Zorbax Poroshell 300SB-C8 column
(0.5 mm diameter  75 mm length, containing 5 lm par-
ticles with 300 Å pores) and mass spectra of the intact
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RVEcTM proteins was acquired in positive mode using a
fragmentor voltage of 225 V, a capillary voltage of 4000 V,
and an m/z range of 100–3527. The instrument was cali-
brated using the Agilent ES-TOF tuning mix to give an ac-
curacy of 0.3 parts per million (ppm) and mass correction
was maintained during the acquisition with the Agilent API-
TOF Reference mass solution. The acquired spectra were an-
alyzed using the Agilent Mass Hunter Qualitative analysis
software. The background was subtracted before de-convolu-
tion of the multiple charge state spectrum to remove the sig-
nals from internal reference masses and some of the baseline
noise. The de-convolution parameters were as follows: mass
range of 10000.00–35000.00 atomic mass units (amu) and
spectral window of 600.00–2500.0 m/z.
Determination of Residual Kanamycin. This method
detects the presence of kanamycin to the limit of 2 lM or
approximately 1 lg/mL. Samples were analyzed both as
spiked with kanamycin (2 lM final concentration) and neat
with 5 mL of sample spiked whereas another 5 mL remained
unspiked. Hereafter, both spiked and unspiked sample will be
generically referred to as ‘‘the samples.’’ The samples were
then processed independently in quintuplicate. Controls were
run spiked and unspiked using the buffer without RVEcTM.
Sample isolation and clean-up: Solid-phase extraction
(SPE) cartridges were processed in parallel using a vacuum
manifold at a flow rate of 2 ml/min or less. Carboxylic acid
SPE cartridges (J. T. Baker speed disk # 8172-06, 10 lm,
100 mg, 3 mL capacity) were preconditioned by applying 2
mL of methanol, 1 mL of purified water, and then equili-
brated with 2 mL of 50 mM sodium phosphate buffer, pH
7.4. An aliquot, 925 lL, of the sample was applied to a SPE
cartridge, washed with 2 mL of 50 mM sodium phosphate
buffer, pH 7.4, 4 mL of 12.5 mM sodium tetraborate, pH
9.0, and finally with 3 mL of purified water and allowed to
dry under vacuum. The samples were eluted by adding 2 mL
of 100 mM sodium tetraborate, pH 10.5, drying the car-
tridges under vacuum, and applying an additional 1 mL of
the same buffer to the cartridge. The pH of the eluate was
verified to be between 10 and 10.5 to ensure elution. The
eluate was used in the subsequent steps.
Fluorescent Labeling: The fluorescent label stock solution
was prepared by dissolving 1 mg of Alexa-Fluor
VR
488 (Invi-
trogen, catalog #30005) in 100 lL dimethyl sulfoxide
(DMSO). The stock was stored as 10 lL single-use aliquots at
20C. The stock was diluted 80-fold with purified water on
the day of use. For each sample, 50 lL of sodium carbonate,
pH 8.2 was added to 240 lL of sample. The labeling reaction
was started by addition of 40 lL of label working solution.
The reactions were either incubated in the dark at ambient tem-
perature for 1 h or at 60C for 10 min. After the incubation pe-
riod, the reaction was quenched by the addition of 20 mM Tris
base. Water (160 lL) was added to the sample and the sample
was mixed before analysis by capillary electrophoresis.
Analysis by Capillary Electrophoresis: Capillary electro-
phoresis was performed on a Beckman Coulter P\ACE MDQ
system with laser-induced fluorescence (LIF) detection that
used an argon laser with an excitation line at 448 nm and
monitoring emission at 520 nm. Uncoated, bare capillaries
Table 1. Standard Analytical Methods for RVEc
HPLC Method Column Type Manufacture Solvent (In H2O-HPLC Grade) Conditions
Reverse Phase 4.6  100 mm C4
PN:214TP3410
Grace Vydac, Hesperia, CA
A: 5% CH3CN:0.1% TFA
B: 95% CH3CN:0.085% TFA
100% A !70% B over 10 min
Col. Temp.: 25C at 2.5 mL/min
Detection: 215 nm
Cation Exchange 4.6  100 mm Polysulfoethyl A
PN: 104SE0503
PolyLC, Columbia, MD
A: 50 mM MES, pH 6.4
B: Solvent A þ 1 M NaCl
5-min hold of 100%A after inj.
100% A ! 25% B over 8.5 min
Col. Temp.: 25C at 1 mL/min
Detection: 280 nm
Size Exclusion 7.8  300 mmTSK-GEL
G2000SWXL PN: 08543
Tosoh Bioscience,
Montgomeryville, PA
25 mM sodium acetate
and 300 mM NaCl, pH 5.5
Isocratic over 30 min
Col. Temp.: 25C at 0.6 mL/min
Detection: 214 nm
Tween-20 4.6  150 mm AcclaimVR
Surfactant column
PN: 063201
Dionex, Sunnyvale, CA
A: 5% CH3CN
B: 95% CH3CN
100 A% ! 35% B over 11 min
35% B ! 100% B over 12 min
Col. Temp.: 25C at 1 mL/min
Detection: Evaporative Light
Scattering (Millipore 2420)
PSI ¼ 45, drift tube ¼ 50,
Nebulizer ¼ 45, and
detector gain ¼ 100
Analytical Methods Description
Endotoxin (LAL) Turbidimetric Pyrotell-T type kinetic assay (Associates of Cape Cod, East Falmouth, MA).
Results were considered valid when spike recovery was 50% to 200% of the spiked endotoxin
SDS-PAGE NuPAGE 10% Bis-Tris gels (cat # NP0301) with the MES buffer system (Invitrogen, Carlsbad, CA)
at constant 200 volts. Gels stained with Brilliant Blue R (Sigma PN:B6529 for 1 h and destained
with 10% v/v acetic acid and 35% v/v MeOH in H2O)
Western Blot Gel transferred to a PVDF membrane using 1x NuPAGE transfer buffer containing 10% methanol
and a semi-dry blotting apparatus (BioRad) at 20 V for 20 min
Blocking: 5% w/v NFDM in TBST (20 mM Tris, 500 mM NaCl, 0.05% Tween-20, pH 7.4)-1 h
1st Ab: 1:2000 dil of mouse polyclonal anti dg-RTA in TBST – 1 h
2nd Ab: 1:2000 dil of goat anti mouse horseradish peroxidase (KLP PN:074-1806) in TBST-1 h
Developed: Amersham ECL PlusTM, GE Healthcare PN: RPN2132 and
x-ray film (Kodak BioMax Light-1, PN: 8689358)
E. coli Protein ELISA kit from Cygnus Technologies (Southport, NC)
Host DNA qPCR by Charles River Laboratories-Malvern (Malvern, PA)
Capillary IEF Capillary isoelectric focusing kit (Beckman Coulter PN: 477490) and a Beckman Coulter
P\ACE MDQ system with detection at 280 nm
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75 lm (ID)  60 cm total length with 50 cm to window
(MicroSolv Technologies Corp.) and windows burned in-
house. The separation was performed using a commercially
available dynamic capillary coating system, CElixerTM
(MicroSolv Technologies Corp.). This two-component sys-
tem (initiator solution part number 06025-CE and accelerator
solution part number 06125-CE) supplies the capillary coat-
ing and the separation buffer (pH 2.5). The sample compart-
ment and the capillary cartridge temperature were controlled
at 25C. The separation program contains multiple pressure
rinses at 20 psi as follows: (1) 1 N hydrochloric acid for
2.00 min; (2) 0.1 N sodium hydroxide for 5.00 min; (3)
water for 2.00 min; (4) initiator for 1.00 min; and (5) accel-
erator for 1.00 min. The sample is injected by pressure injec-
tion at 0.5 psi for 5 s and followed with a water plug
injection at 0.1 psi for 10 s. The electrophoretic separation
starts with a 1 min ramp to 25 kilovolts (kV) under normal
polarity (negative terminal on window side of capillary) with
total voltage separation time of 12 min.
Results were interpreted based on a set peak area thresh-
old, 20,000 RFU*min. Samples that were unspiked with
kanamycin peak areas below threshold were reported as
below the detectable limit. Unspiked samples with areas less
than the spiked control but greater than the threshold were
reported as less than 2 lM of kanamycin. Unspiked samples
with areas greater than the spiked control and the threshold
were reported as greater than 2 lM of kanamycin.
Potency of the Vaccine by Ricin Challenge. The potency
of RVEcTM was determined using a modified in vivo assay
previously described.21 Briefly, three groups of 10 female
BALB/c mice were intramuscularly vaccinated at study days
0 and 21 with 20 lg of RVEcTM absorbed to 0.2%
Alhydrogel
VR
. One group of 10 female mice (control mice)
was sham vaccinated with vaccine diluent. One week after
the last vaccination, blood was collected for serological anal-
ysis and the mice were challenged intraperitoneally (i.p.) the
following day with 5, 20, or 50 LD50 of ricin toxin. Control
mice were challenged i.p. with 5 LD50 of ricin toxin. Mice
were observed for mortality or morbidity for 7 days with
percent survival in each group being calculated along with
neutralizing antibody titers and concentration.
Determination of Serum Neutralization Antibody
Concentration and Titer. The neutralizing anti-ricin anti-
body concentration and endpoint titer in the mouse serum
was determined by a colorimetric cell proliferation toxin
neutralization assay (TNA) as previously described.22
Molecular biology and strain development
Construction of RVEcTM Plasmid for Production in
E. coli. The gene for the over-expression of rRTA 1-33/44-
198 was previously obtained by PCR and was ligated into a
plasmid vector containing a T7 promoter;19 this work was
based on the original sequence by Lamb.23 For this study,
the pET24a plasmid was used for the T7-promoter dependent
expression of the RVEcTM gene. The gene for RVEcTM
(rRTA 1-33/44-198) was optimized for expression in E. coli
according to the codon-bias.
Transformation of Plasmids and Screening of RVEcTM
Producing Clones. The RVEcTM pET24a plasmid
(RVEcTM, pET24a-CBI-RVEc) was transformed into the E.
coli BLR(DE3) competent cells (Lot # N70786, Cat. #
69053 Novagen, Madison, WI). The cells were thawed on
ice and 50 ng of plasmid was added to each vial, mixed well
and kept on ice for 10 min. Heat shock was applied for 50 s
at 42C, after which the cells were placed back on ice. SOC
medium (150 lL; Lot # N65145, Cat. # 69319, Novagen)
was added and the transformed cells were allowed to grow
at 37C in an incubator shaker for 1 h. A volume of 50 or
100 lL of each of the transformed cells were plated on LB-
lennox/kanamycin plates (Lot # 10200, MBL). Kanamycin-
resistant colonies were obtained after overnight incubation at
37C. Four colonies were picked and inoculated into 15 mL
LB-Lennox medium (Lot # 10177, MBL) with 50 lg/mL of
kanamycin (Lot # 10135, MBL) and grown overnight in an
incubator shaker at 37C. The overnight cultures from differ-
ent colonies were used as inocula for two flasks per colony
with each flask containing 15 mL TB medium (Lot # 10168,
MBL) with 50 lg/mL of kanamycin. These flasks were incu-
bated at 37C with shaking (250 rpm) and grown to a final
OD measured at 600 nm (OD600) of 0.1. The expression of
RVEcTM was induced with a final concentration of 1 mM b-
isopropylgalactoside (IPTG) (EMD Biosciences, San Diego,
CA). After induction, the cultivation temperature was
reduced to 30C and 500 lL samples were taken at 2 and 6
h post-induction and centrifuged at 13,200 rpm for 5 min at
room temperature. To evaluate expression of the RVEcTM, 1
mL of 1 OD600 (or 5 OD600 for small scale analysis) of each
cell pellet was dissolved into 200 lL of 1X working solution
of SDS-PAGE, heated in boiling water for 10 min, and cen-
trifuged at 16,000g for 10 min. A volume of 10 lL of super-
natant was loaded per well into NuPAGE 12.5% SDS-PAGE
gels (Invitrogen, Cat. # NP0302BOX). Western blots were
performed on the samples as described above.
Fermentation of E. coli BLR(DE3) 1 pET24a-CBI-
RVEcTM
A semi-defined medium was used for both shake flask and
fermentation studies and is a modification of Kilikian et al.24
The medium consisted of 13.0 g/L potassium phosphate,
monobasic (KH2PO4), 10.0 g/L potassium phosphate, dibasic
(K2HPO4), 3.0 g/L ammonium phosphate, dibasic
[(NH4)2HPO4], 4.6 g/L sodium phosphate, monobasic, mono-
hydrate (NaH2PO4.H2O), 30.5 g/L yeast extract, and 0.5 mL/L
of antifoam KFO 673.25,26 After sterilization, 1.2 g/L of 2 M
magnesium sulfate, heptahydrate (MgSO4.7 H2O), 8 g/L glu-
cose, 50 lg/mL of kanamycin, and 3 mL/L of a modified E.
coli trace elements solution were added by filter sterilization.27
The modified E. coli trace elements solution had the following
composition: 27 g/L of ferric chloride, hexahydrate
(FeCl3.6H2O), 2 g/L of zinc chloride (ZnCl2), 2 g/L of cobalt
chloride, hexahydrate (CoCl2.6H2O), 2 g/L of sodium molyb-
date, dehydrate (Na2MoO4.2H2O), 1 g/L of calcium chloride,
dihydrate (CaCl2.2H2O), 1.27 g/L of cupric chloride, dihydrate
(CuCl2.2H2O), 0.5 g/L of boric acid (H3BO3), 8.4 g/L of ethyl-
enediamine tetraacetic acid (EDTA), and 100 mL/L of concen-
trated hydrochloric acid (HCl). The feed solution for the fed-
batch phase consisted of 30 g/L of yeast extract, 50% w/w of
glucose, and 22.7 g/L of MgSO4.7H2O. The medium was sup-
plemented with 30 g/L of yeast extract to overcome the isoleu-
cine auxotrophy requirement of the BLR strain.28
A 250 lL aliquot of a glycerol stock was the inoculum
for 300 mL of the semi-defined medium in a 1 L conical
flask. After 12–14 h of growth at 37C and 250 rpm in a
Innova 4200 incubator shaker (New Brunswick Scientific,
Edison, NJ), the 300 mL shake-flask culture with an OD600
of 2–4 was used as the inoculum for 6 L of fermentation
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medium in a 19 L fermentor (NLF Bioengineering AG,
Switzerland). The fermentation was monitored for OD, pH,
and off-gas using a Thermo Fisher VG Prima dB Process
mass spectrometer (Thermo Fisher Scientific), WCW, and
glucose concentration. The temperature was maintained at
37C during the batch and during the fed-batch phase until
the OD reached 40–50. The pH set point was maintained at
7.0 throughout the entire fermentation. The oxygen concen-
tration was kept at [40% saturation using a standard cas-
cade by supplementing the air flow rate of 6 L/min with
pure oxygen after the agitation reached 800 RPM. The vessel
pressure was maintained at 0.2 bar. Once the glucose was
consumed as indicated by dissolved oxygen (D.O.) spiked
during the batch phase, a feed rate of 5 g/L/h of feed solu-
tion [30 g/L yeast extract, 50% (w/w) glucose, 22.7 g/L of
MgSO4.7H2O, and 100 lg/mL of kanamycin] was started
until the WCW reached 40–60 g/L. At this point, induction
was started by first adjusting the fermentor temperature to
22C and then adding IPTG to a final concentration of 1
mM based on estimated volume of the fermentor contents. A
second fed-batch phase was started, consisting of 2 h at 5 g/
L/h, 2 h at 4 g/L/h, 2 h at 3 g/L/h, and 1 h at 2 g/L/h to
maintain the glucose concentration below 1 g/L. At this
point (7 h induction time), the cells were harvested by cen-
trifugation using an Evolution RC Sorvall centrifuge at
11,344g for 30 min and the cell paste was stored at 20C.
The average yield was 24 mg of RVEcTM/g WCW or 1.2 g
of RVEcTM/L fermentation broth.
Purification of RVEcTM at the benchscale
Frozen cells were suspended at 10% w/v solids (20 g in
200 mL of 25 mM Bicine, pH 9.0) and disrupted by two
passes through a Model EH-110 microfluidizer (Microflui-
dics Corp., Newton MA) at a pressure of 17,000–20,000 psig
at 10–11C. The homogenate suspension was centrifuged at
11,344g for 70 min at 4C, the supernatant was diluted five-
fold with 50 mM MES, 70 mM NaCl, pH 5.5 to adjust the
pH to 5.70 and the conductivity below 3 mS/cm. The
diluted lysate was filtered through a 0.8 lm/0.45 lm Fluoro-
dyne II membrane (Pall Corp., East Hills, NY). RVEcTM
content was monitored by the SCX-HPLC method.
Column chromatography was performed using a BioCad
Vision Chromatography system (Applied Biosystems, Foster
City, CA). Dynamic resin-binding studies determined that
maximum recovery of RVEcTM was achieved when the
RVEcTM load did not exceed 2.5 mg of RVEcTM per mL of
resin for all columns. The clarified lysate was loaded onto a
5.0  18.5 cm SP-Sepharose FF column (Waters AP-5,
Millipore, Milford, MA) at a linear velocity of 150 cm/h. The
column was washed with five column volumes (CVs) of 50
mM MES, 70 mM NaCl, pH 5.50, followed by a 10 CV
gradient from 70 mM to 250 mM NaCl in the same MES
buffer, with detection at 280 nm (UV280). The column was
cleaned with two CVs of 1 M NaCl in the same MES buffer.
The RVEcTM peak was collected and diluted three-fold with
50 mM MES, pH 5.50, to bring the conductivity below 7 mS/
cm and passed through a 370 mL Q-Sepharose FF (5  19
cm) column at a linear flow rate of 150 cm/h. Under these
conditions the RVEcTM did not bind to the column resulting
in a negative purification step. The flow-through was directly
loaded onto a 360 mL SP-Sepharose HP column (GE Health-
care BioSciences, Piscataway, NJ) (5.0  18 cm, Waters
AP-5) at a linear flow rate of 120 cm/h pre-equilibrated with
50 mM MES, pH 5.50. The elution protocol is as follows
using 50 mM MES, pH 5.50: (1) wash with one CV of 70
mM NaCl; (2) a gradient of 10 CVs from 119 mM to 166
mM NaCl; (3) an isocratic elution step at 166 mM NaCl; and
(4) an isocratic final elution step at 1 M NaCl. During the 10
CV gradient, fractions were collected across the asymmetric
elution peak, first at 0.25 CV per fraction, then 1.0 CV per
fraction and then at 3 CV per fraction. Fractions were
analyzed by SDS-PAGE, Western blot, and SCX-HPLC; those
that contained RVEcTM at purities of 99% or greater based on
SCX-HPLC were pooled. Tween-20 was added to the pooled
product at a final concentration of 0.12% w/v before the final
diafiltration. The pooled fraction was first concentrated to 1
mg of RVEcTM/mL using a PES 5,000 molecular mass cutoff
(MWCO) membrane (2 ft2, 0.5 mm channel height) mounted
in an OPTISEP 3000 membrane holder attached to a Model 5
cross-flow membrane filtration unit (SmartFlow Technologies,
Apex, NC) and processed at ambient temperature. Once the
RVEcTM was concentrated to 1 mg/mL, a five-fold constant
volume diafiltration step using 20 mM succinate, 0.1 M NaCl,
pH 6.5 was performed. The concentration of RVEcTM was
calculated from the absorbance of the solution at 280 nm with
the spectrophotometer blanked against pure water using an
extinction coefficient of 0.91 for a 1 mg/mL solution. Before
bulking, the Tween-20 concentration was measured (Table 1)
and the concentration of Tween 20 was readjusted to ensure a
concentration of 0.12% w/v. The final product was analyzed
by SDS-PAGE, Western blot, HPLC (SCX, RP, and SEC),
intact mass, peptide mapping, Tween-20, residual kanamycin,
residual endotoxin, residual host DNA, residual host protein,
and potency.
Process scale-up
The bench-scale process was scaled up five-fold and run in
a manner identical to how the process would be performed in
the cGMP suite. The fermentation was identical to that
described above and cell mass was frozen for at least 24 h
before use. All columns, equipment, tubing, and storage con-
tainers were depyrogenated by overnight treatment with 0.5 N
sodium hydroxide (NaOH). Pyrogen-free water was generated
by filtration of reverse-osmosis purified water through a
Kleenpak Posidyne filter from Pall. Buffers were prepared
with this water, but only the buffers for the final two steps
were tested for endotoxin before use. Purification was per-
formed with a process chromatography skid (SmartFlow Tech-
nologies, Inc S/N: 5037) equipped with inline UV-visible
(Model 660), pH (Model 600), and conductivity (Model 620)
detectors from Wedgewood Technologies (San Carlos, CA).
For the engineering runs, 100 g of frozen cell paste was
thawed and the cell paste was suspended in 1 L of 25 mM
Bicine, pH 9.0. The cells were lysed by microfluidization as
described above. After centrifugation for 70 min at 4C and
11,344g, the supernatants were combined (1.2 L total vol-
ume) and transferred into a 20 L HyClone
VR
2D BioProcess
Containers
VR
bag (BPC) (Thermo Fisher, Logan, UT) using a
peristaltic pump. From this point forward, unless otherwise
noted, processing was performed in a closed system using
appropriately sized Hyclone bags. The column size for each
of the three chromatography steps were 10 cm  21 cm 1.65
L SP-Sepharose FF column, 10 cm/21 cm 1.65 L Q-Sepharose
FF, and a 10 cm  22 cm 1.73 L SP-Sepharose HP column.
The elution conditions for all columns are as described above.
The RVEcTM pool was concentrated to 1.5 L and diafiltered
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as described above using a SmartFlow Technologies, Inc
Model 10 cross-flow membrane filtration system with an
OPTISEP 3000 equipped with a 5,000 MWCO Regenerated
Cellulose (RC) membrane, 0.5 mm channel height and area of
0.196 m2. The final product was filtered through a Fluorodyne
II (0.2 lm) filter, after which 1,015 mL of a 1.15 mg/mL so-
lution of RVEcTM was obtained (1.17 g). RVEcTM is routinely
stored at 80C.
cGMP production of RVEcTM
The cGMP production of RVEcTM was performed in the
UN-L BPDF cGMP suite equipped with a New Brunswick
Scientific (NBS) MPP80 fermentor and a NBS gas blending
system for addition of oxygen. Fermentation followed the
same process as previously described above except for an
increase in volumes. Cells were harvested by centrifugation
for 30 min at 4C 11,344g using an Evolution RC Sorvall Cen-
trifuge. The exact same downstream processing equipment
described above was used for the cGMP run. The Purification
Development Laboratory and the cGMP suite have the exact
same downstream processing equipment, minimizing technol-
ogy transfer into the cGMP suite. The shakedown runs per-
formed in the cGMP suite and the cGMP run processed 400 g
of cell paste which is a 20-fold scale up from the bench-scale.
The column sizes for the cGMP runs were increased fourfold
over what was previously described above.
Results
Optimization of the RVEcTM fermentation
A T7-promoter dependent expression system was used to
express the E. coli codon-optimized RVEcTM gene using the
pET24a expression vector. We opted to use the recA, lon,
and ompT deficient E. coli strain BLR(DE3) to minimize the
potential for plasmid recombination.29 This E. coli strain has
a mutation that prevents the biosynthesis of isoleucine,
resulting in a significant decrease in the rate of cell growth
and product yield during fermentation using a defined me-
dium.28 The defined medium used in these studies was sup-
plemented with 30 g/L of yeast extract (now a semi-defined
medium), which was a source of additional nutrients and
served as a source of isoleucine. The glucose feed solution
was also supplemented with 30 g/L of yeast extract.
Fermentation parameters were optimized for RVEcTM
quality, that is, purity and stability, so as to meet the require-
ments for production of Phase I clinical material. The yield
of RVEcTM per gram of wet cell mass was more than suffi-
cient (24–37 mg/g WCW), allowing optimization studies to
focus on the quality of the RVEcTM. Shake flask and fermen-
tation studies evaluated a glucose-supplemented animal-free
complex medium. Shake flask inocula, which was the same
complex medium used for fermentation, grew slowly reaching
an OD of 1–2 over a 12 h compared to an OD of 3–4 using a
semi-defined medium. The batch and fed-batch phases of fer-
mentation using a complex medium only reach ODs of 15–20
before induction. Evaluation of the whole cell lysate by West-
ern blot from shake flask and fermentation growth before
induction showed low levels of RVEcTM (data not shown).
This unintended ‘‘auto-induction’’ was detrimental to cell
growth and productivity. It was postulated (though not con-
firmed) that trace amounts of lactose in the complex media
were causing unintended induction as seen by Studier.29 Given
that BLR(DE3) is an isoleucine auxotroph, a defined medium
supplemented with either isoleucine or yeast extract was
investigated. The best growth and RVEcTM production was
observed with the medium supplemented with yeast extract.
The effect of temperature on the production of RVEcTM
was investigated. The batch and fed-batch temperature was
37C and once 100 g/L of WCW was reached the tempera-
ture was reduced to either 22C, 26C, and 37C and 1 mM
IPTG was added once the temperature reached the new set
point. Induction occurred for 24 h and samples were ana-
lyzed by SXC-HPLC (Figure 1). The results indicated that
22C or 26C were preferred over 37C with 22C selected
because of the slightly slower growth rate and the cells con-
tinued to produce RVEcTM.
The effect of residual glucose concentration during the
induction was evaluated. Studies showed that glucose con-
centration in excess of 1–2 g/L during induction reduced the
production of RVEcTM by 50% as compared to glucose lev-
els maintained between 0.1 and 0.4 g/L (data not shown).
Glucose feed rates were optimized to maintain residual glu-
cose concentrations to\0.5 g/L. The intracellular production
of RVEcTM increases up through 24 h of induction and pro-
duced up to 80 mg RVEcTM/g WCW (data not shown).
Analysis of the cell lysates during induction by SCX-HPLC
(Figure 2) showed the accumulation of a less basic
Figure 1. Effect of induction temperature on the production of
RVEcTM per g WCW as determined by SCX-HPLC.
Figure 2. Production of RVEcTM during fermentation with
semi-defined medium after induction.
The SCX-HPLC chromatograms correspond to 0, 3.7, 7.2, 12.3,
15.0, 17.9, 21.0, and 23.9 h induction time.
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contaminant (9.6 min elution time) starting after 7 h of
induction. Attempts to remove the contaminant during purifi-
cation were unsuccessful and the decision was made to
reduce the induction time to 7 h to avoid the basic contami-
nant. The time course of a fermentation is presented in Fig-
ure 3 and shows the production of RVEcTM, the WCW,
glucose feed profile, and the residual glucose level, which
was maintained below 0.4 g/L.
Purification of RVEcTM at the benchscale
and engineering runs
Cell Disruption. The theoretical isoelectric point for
RVEcTM is 7.40 and cell disruption studies were optimized
from pH 6.5 to 10.5 with NaCl concentration from 0 to 2 M.
Small-scale (1.5 mL) cell disruption studies were performed
with a Bead Beater (BioSpec Products, Bartlesville, OK) and
samples analyzed by SDS-PAGE and Western blot. Results
indicated that the best condition for release of RVEcTM was
25 mM Bicine, pH 9.0, 2 mM EDTA, and no NaCl. As the
NaCl concentration increased so did the amount of RVEcTM
that precipitated. The yield of RVEcTM using a microfluid-
izer at 17,000 psig after two passes averaged 20% higher as
compared to the bead beater. Analysis of the supernatant af-
ter frozen cells were thawed before cell disruption showed
that approximately 60% of the RVEcTM was released due to
the thawing process alone. A study showed that processing
frozen cells (20C) yielded about 25% more RVEcTM than
fresh cells using the standard disruption procedure of two
passes at 17,000 psig. Based on this study freezing at 20C
was instituted as an overnight hold step after fermentation.
Capture Column—SP Sepharose. The optimal pH for
release of RVEcTM from cells by disruption is basic and thus
several anion exchange resins were screened for capture of
RVEcTM. It was found that even at pH 10.5, the binding of
RVEcTM to Q-Sepharose was not satisfactory and resulted in
losses of RVEcTM in the flow-through. This is consistent
with previous purifications results.19–21 Interestingly, a num-
ber of impurities bound to the Q-Sepharose and eluted at 1
M NaCl with no RVEcTM detected in the 1 M fraction, indi-
cating that Q-Sepharose would be a suitable negative purifi-
cation step, which is discussed later.
RVEcTM binds tightly to cation exchange resins19 at pH\
7.0. Before initiating these studies, the lysate was exchanged
from pH 9 to pH 6 using a five volume diafiltration with 50
mM MES at pH 6 using a 5,000 MWCO PES ultrafiltration
membrane. Unfortunately, this resulted in RVEcTM losses as
high as 73%. We determined that RVEcTM was susceptible
to precipitation below pH 9 and exposure to a liquid-air
interface. Every effort was made to avoid a air-liquid inter-
face, which proved difficult with a cross-flow membrane fil-
tration system. The alternative was to dilute the homogenate
fivefold with 50 mM MES pH 5.5, 2 mM EDTA, and 10
mM NaCl (note: NaCl was added to increase the conductiv-
ity as much as possible and still bind RVEcTM to the SP-
Sepharose). The addition of 10 mM NaCl was helpful in
reducing the amount of contaminants binding to the SP-
Sepharose FF column. The reduction in pH from 6.0 to 5.5
improved the binding of RVEcTM and it was critical to
reduce the conductivity by dilution to at least 4 mS/cm to
maximize binding to the SP-Sepharose FF column. Using
this approach RVEcTM losses were less than 4% before load-
ing onto the capture column.
The optimum dynamic binding capacity of four different
cation exchange resins, that is, SP-Sepharose FF, Source
30S, SP-Sepharose HP, and Toso Haas SP-650M, was \3
mg/mL as RVEcTM broke through all of the resins with
loads above 3 mg/mL. To ensure maximum recovery from
the capture step, the RVEcTM loading density was main-
tained at 2.5 mg/mL of resin or less. There was no obvious
difference in performance between all four resins, so SP-
Sepharose FF was selected as it was the least expensive
resin. Purity of the RVEcTM pool (fraction 2—Figure 4), as
judged by SCX-HPLC was [95% and the average yield for
10 runs from bench-scale to cGMP was 87% (Table 2).
Second Purification Column—Q Sepharose. The second
step was a negative purification step using a Q-Sepharose
column which was very effective at removing a majority of
host cell protein contaminants (Figure 5). It was important to
reduce the conductivity to at least 6 mS/cm using a threefold
dilution using 50 mM MES, pH 5.5. This conductivity was
necessary for RVEcTM to bind to the final cation exchange
polishing column.
Third Purification Column—SP-Sepharose HP. The Q-
Sepharose flow-through was loaded directly onto a high per-
formance SP-Sepharose HP column at 2.5 mg RVEcTM/mL
of resin. A shallow 15 CV NaCl gradient from 119 mM to
190 mM NaCl eluted the RVEcTM in an asymmetric peak
Figure 3. Profile of temperature, wet cell weight, RVEcTM, and glucose concentration during the cGMP run.
1042 Biotechnol. Prog., 2011, Vol. 27, No. 4
(Figure 6) and separated contaminants that eluted before and
after the RVEcTM peak as determined by SCX-HPLC (Figure
7). The criterion for pooling RVEcTM was that fractions (5–
8) must be greater than 99% pure (Figure 6).
Final Diafiltration and Bulking Step. The RVEcTM was
susceptible to precipitation and was particularly sensitive to
precipitation at an air–liquid interface. Precipitation started
as white ‘‘stringy’’ filaments that were visible upon close
inspection and was independent of protein concentration
(0.2–1 mg/mL). It was critical during cross-flow membrane
filtration that bubbles were removed from the recirculation
path and that the liquid returning back to the tank was com-
pletely submerged to eliminate any liquid–air interface. Even
with these precautions there was still some precipitation.
Three different detergents, Tween-20, Tween-80, and Triton
X-100, were evaluated at concentrations from 0.05% to 0.2%
w/v in an effort to minimize precipitation. Just before the
concentration/diafiltration step, the detergent was added at
the respective concentration. The diafiltration buffer, 20 mM
sodium succinate pH 6.50 and 0.1 M NaCl, did not contain
detergent. The selection criterion was based on visual obser-
vation of precipitate both during and after diafiltration. Both
Tween-80 and Triton X-100 showed noticeable precipitation
at all concentrations, while Tween-20 showed very little to
no precipitation at the 0.1–0.2% (w/v). At the completion of
the diafiltration, the Tween-20 concentration was measured
and it was found that the concentration was reduced by 50
to 70% after five diafiltration volumes. Tween-20 was added
back to the final retentate at a concentration of 0.15% (w/v).
Analysis of the RVEcTM Bulk Drug Substance. The sum-
mary of analysis of the RVEcTM bulk drug substance (BDS)
for all runs is presented in Table 3. RVEcTM is 100% pure
based on SCX-HPLC and RP-HPLC, 99.5% pure based on
SEC-HPLC (Figure 8), and is a single band by SDS-PAGE
and Western blot for all runs and capillary isoelectric focus-
ing showed a variance in the pI ranging from 7.14 to 7.22
(Table 3). Residual host cell proteins for all runs range from
1.42 to 7.2 ng/mg RVEcTM. The residual host cell DNA for
cGMP Shakedown Run 1 was reported below the detection
limit of \80 pg/mg RVEcTM, while cGMP Shakedown Run
2 and the cGMP Production Run were \10 pg/mg RVEcTM.
Charles Rivers Laboratory-Malvern, who was contracted to
Figure 4. Chromatogram for SP-Sepharose FF capture column and SDS-PAGE of the fractions.
L ¼ load, FT ¼ flow-through, W ¼ Wash, F1 – F4 ¼ fraction 1 through fraction 4.
Table 2. Summary of the Production Yield of RVEcTM for All Runs
Fermentation g
RVEc/ kg WCW
% Yields Across Each Step based on SCX-HPLC
Cell Rupture þ
5X Dilution
Capture
SP-FF
3X
Dilution
Negative
QS-FF
Polishing
SP-HP UFDF
Overall
Yield
g RVEc/
kg WCM
RVEc Benchscale Run 1 37.5 96.1% 95.9% 87.4% 93.7% 87.0% 91.3% 59.9% 22.5
RVEc Benchscale Run 2 37.5 94.4% 102.4% 90.0% 104.1% 84.1% 82.0% 62.5% 23.4
RVEc Benchscale Run 3 37.5 100.0% 102.0% 100.3% 96.9% 82.8% 90.0% 73.9% 27.7
RVEc Benchscale Run 4 26.1 100.0% 91.5% 100.0% 97.8% 70.7% 90.0% 56.9% 14.9
RVEc Benchscale Run 5 30.0 87.0% 100.0% 97.5% 98.0% 71.2% 90.0% 53.3% 16.0
RVEc Engineering Run 1 27.1 78.5% 95.2% 81.1% 97.0% 83.0% 76.2% 37.2% 10.1
RVEc Engineering Run 2 29.2 93.8% 84.8% 119.0% 81.6% 74.9% 74.1% 42.9% 12.5
RVEc Shake Down Run 1 24.8 44.4% 67.5% 100.0% 91.0% 90.1% 105.7% 26.0% 6.4
RVEc Shake Down Run 2 25.5 79.1% 77.2% 100.0% 93.7% 107.1% 79.2% 48.5% 12.4
RVEc cGMP Run 23.8 99.9% 73.1% 100.0% 63.7% 90.4% 99.9% 42.0% 10.0
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perform the assay, was able to improve the sensitivity of the
assay. Kanamycin was undetected in all final product sam-
ples and is not reported in Table 3.
RVEcTM was characterized at the molecular level using
intact mass analysis. The ESI-TOF determined an intact mass
range of 21447.1 to 21447.5 amu for all runs listed in Table 3,
which compares favorably to the theoretical mass of 21447.
On the basis of the charge envelope, it was determined by
intact mass analysis that the percentage of RVEcTM missing
an N-terminal methionine ranged from 6.5% to 12.1%. LC-
MS/MS was able to identify the N- and C-termini peptides and
determined that a majority of the RVEcTM N- and C- termini
were intact. LC-MS/MS also determined that methionines 165
and 179 were partially oxidized.
The stability of the RVEcTM BDS was evaluated at 4C
and 80C over 3 weeks. RVEcTM did not show any signs
of proteolytic degradation at 4C or 80C after 3 weeks
based on SDS-PAGE (Figure 9).
Potency Results. The data for the potency assay on vari-
ous lots of RVEcTM are summarized in Table 3. For all the
lots that were tested, 90–100% of the mice survived for 7
days after an i.p. challenge with 5 LD50s of ricin toxin. Sur-
vival rate at various ricin LD50s were used to calculate the
midpoint of the dose-response curve (ED50) by probit analy-
sis (Table 3). In all 10 lots tested, the ED50 ranged from 300
to 700 lg/kg for mice vaccinated with two doses of RVEcTM
whereas the ED50 for diluent control mice was 10–20 lg/kg
The anti-ricin neutralization antibody concentrations as
determined by the TNA are summarized in Table 3. With the
exception of lot shakedown run 2 (67%), 90–100% of the
mice vaccinated with the other nine lots of RVEcTM developed
anti-ricin neutralization antibodies. For all 10 lots, the anti-
ricin neutralizing antibody concentration was 54–163 lg/mL.
None of the buffer controls developed anti-ricin antibodies.
Discussion
The biopharmaceutical industry, in concert with the FDA,
has implemented a Quality by Design (QbD) approach to
process development and manufacturing. QbD builds quality
Figure 5. Chromatogram for the Q-Sepharose FF. SDS-PAGE
of the fractions.
L ¼ load, FT ¼ flow-through (RVEcTM), F ¼ 1 M NaCl wash.
Figure 6. Chromatogram of the SP-Sepharose HP column.
The fractions are indicated by the vertical marks (MRK) on the chromatogram.
Figure 7. SCX-HPLC chromatograms of the fractions from
the SP Sepharose HP column.
Numbers to the left are the fraction numbers from the chromat-
ogram shown in Figure 6.
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and robustness into the product starting with product devel-
opment through commercial launch and is evident through
all stages of process development, scale-up and cGMP man-
ufacturing. A bench-scale process was developed that met
expectations for yield, quality and potency and served as a
reference point for process scale-up and manufacturing. The
robustness and consistency of the bench-scale process was
based on five different bench-scale runs with three purifica-
tions performed with the same cell mass (runs 1, 2, and 3)
and two purifications from separate fermentations (runs 4
and 5). Runs 1–3 averaged 65% overall recovery from the
same fermentation and runs 4 and 5 had recoveries of 57
and 53%, respectively. The average yield for all five bench-
scale runs was 61%. The analytical testing of the products
from all 5 runs is presented in Table 3. The purity of
RVEcTM based SCX, RP, and SEC HPLC is 99.5% or
greater, the percentage of RVEcTM containing an N-terminal
methionine ranged from 91 to 93.7%, host protein ranged
from 1.47 to 6.71 ng/mL and the MW based on intact mass
analysis ranged from 21447.1 to 21447.5 for all 5 runs.
These results indicate a consistent and robust process at the
bench-scale and are a starting point for establishing the tech-
nical specification for the release tests for the cGMP product.
An approved Standard Operation Procedure (SOP) was gen-
erated for all analytical methods listed in Table 3. The
Table 3. Summary of RVEcTM Characterization and Analytical Results for All Runs
Run
Bench
Scale
Run 1
Bench
Scale
Run 2
Bench
Scale
Run 3
Bench
Scale
Run 4
Bench
Scale
Run 5
Scale
Up
Run 1
Scale
Up
Run 2
cGMP
Shake
Down
Run 1
cGMP
Shake
Down
Run 2
cGMP
Run
Strong Cation Exchange
HPLC (%)
100 100 100 100 100 100 100 100 100 100
Reverse Phase HPLC (%) 100 100 100 100 100 100 100 100 100 99
Size Exclusion HPLC
(%) (% monomer)
99.6 99.5 99.6 99.6 99.3 99.7 99.4 99.6 99.2 99.9
SDS-PAGEA (%) [95 [95 [95 [95 [95 [95 [95 [95 [95 [95
2100 BioanalyzerB (%) 100 100 100 100 100 100 100 100 N/D N/D
N-terminal Met Content (%) 93.5 93.6 93.7 92.0 91.0 91.1 92.3 86.3 89.0 87.9
Tween-20, % w/w 0.08 0.11 0.12 0.12 0.08 0.14 0.08 0.18 0.16 0.16
Cap. Isoelectric Focusing (pI) N/D N/D N/D N/D N/D 7.10 7.12 7.18 7.14 7.22
Intact Mass Analysis (Da) 21447.1 21447.5 21447.4 21447.4 21447.4 21447.4 21447.3 21447.4 21447.5 21447.1
Endotoxin (EU/mL) N/D N/D N/D N/D N/ D 1.33 0.91 8.61 \0.098 1.1
Host Cell DNA (pg/mL) \5000 \5000 \5000 \5000 \5000 \5000 \5000 \80 \10 \10
Host Cell Protein (ng/mL) 4.45 5.20 4.29 1.47 6.71 1.64 1.42 7.55 5.70 7.2
Potency Assay
% of Mice Surviving 5 LD50 100 100 100 100 90 100 89 100 95 100
ED50 (lg/kg) 380 708 380 580 340 360 420 460 300 500
% Immune Response in TNA 100 100 100 100 100 100 100 100 67.3 93.3
Anti-ricin neutralization
Ab (lg/ml)
163.1 128.9 120.7 91.0 109.8 58.0 136.0 96.8 54.5 74.1
N/D, not determined.
Figure 8. Strong cation exchange (A), reverse phase (B), and
size exclusion (C) HPLC of the RVEcTM BDS.
Figure 9. SDS-PAGE of RVEcTM BDS from 1 to 5 lg (A).
SDS-PAGE (5 lg) of RVEcTM BDS stored at 4C and 80C
for 3 weeks (B).
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standard process is to qualify all release methods which
allows for the SOPs to be finalized and in combination with
all of the results from the bench-scale and scale up activities,
an approved technical specification document is generated
that is used for release of the cGMP material. In this case,
the methods were not qualified, but 7 different process runs
were performed at 2 different scales with full testing with
the approved SOPs to generate the technical specification
document.
The average yield of the process scale-up runs was 40%
which is 21% less than the bench scale runs. The major dif-
ference between the bench-scale and process scale-up runs
was going from a very low hold-up volume Biocad system
to a process chromatography system with a bubble trap and
1=2’’ sanitary piping, which will reduce the resolution of the
process chromatography system. Tighter cuts of the product
peak were made to insure the desired quality was maintained
(Table 3) at the expense of yield.
cGMP shakedown run 1 showed a significant reduction in
the yield across the first step (44%), as compared to cGMP
shakedown run 2 and the cGMP run. This was attributed to
the method of mixing of the initial cell paste before cell dis-
ruption. The bench-scale studies used a high-shear mixer to
re-suspend the frozen cell paste for a very short period of
time (1–2 min). It was determined that before the first pass
through the homogenizer, nearly 60–70% of the cells were
lysed due to the freeze-thaw. When the process was trans-
ferred into the cGMP suite, the mixing time was arbitrarily
set to 30 min in the batch records. It was found that there
was a significant loss of RVEcTM during this extended high-
shear mixing and it is hypothesized that the RVEcTM
released from the freeze-thaw was precipitating during the
high-shear mixing. The high-shear mixer was replaced with
a marine impeller mixer for re-suspension of the cell mass,
which corrected the problem as seen by the yields for the
cell disruption and 5X dilution step for cGMP shakedown
run 2 and the cGMP run (Table 2). The average overall yield
for the process scale-up runs, shakedown run 2, and the
cGMP run was 43%.
The release testing and characterization of the cGMP runs
are presented in Table 3. The purity by SXC, RP, and SEC
HPLC was identical to the bench-scale runs and the process
scale-up runs. The host protein increased very slightly 5.70–
7.55 ng/mL (or ng/mg), which is well within expected limits
and the host DNA was less than 10 pg/mL (pg/mg). With an
upper dose of 100 lg the maximum amount of host protein
and DNA would be 0.76 ng and\1 pg, which is well below
the FDA’s recommendations for host protein and DNA.30
The process as described is able to produce 1.2 g
RVEcTM/L of fermentation broth and assuming a dose of
100 lg, the yield is 12,000 doses per L of fermentation broth.
A 60 L fermentation would produce 720,000 doses. The fer-
mentation is the step that could have the highest impact on
increasing yield. As mentioned, it was possible to produce 80
mg RVEcTM/g of wet cells by increasing the induction from 7
to 24 h. The problem was that a ‘‘basic’’ impurity based on
SCX HPLC started to show up and a decision was made to
shorten the induction so as to eliminate the need to reconfig-
ure the purification process to remove this impurity.
Further process optimization and scale-up will be depend-
ent on what the human dose and schedule is determined to
be and the total amount of vaccine required for clinical eval-
uation and stockpiling. A Phase 1 escalating, multiple-dose
study to evaluate the safety and immunogenicity of RVEcTM
in healthy adults is underway beginning in April 2011 at
USAMRIID. Results from this study will provide initial data
upon which future developmental needs are required.
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